SUNNYVALE, Calif., Oct. 29 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 40 accepted abstracts highlighting the use of the CyberKnife Robotic Radiosurgery System will be presented as posters and presentations at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place in San Diego from October 31-November 4.
Presentations related to CyberKnife radiosurgery cover a growing array of clinical indications including prostate, intracranial, head and neck, lung, renal, spine and optic, as well as technical presentations including two breast cancer studies and a cost-effectiveness analysis for pancreatic cancer. Additionally, three abstracts from ongoing Accuray-sponsored clinical studies will be presented, which include the inoperable lung cancer study, and the two prostate cancer studies.
Two talks on the use of CyberKnife radiosurgery for the treatment of prostate cancer will be presented on Tuesday, November 2 beginning at 11:45 a.m. PT:
Accuray will be exhibiting at booth #1313 and will host in-booth presentations on topics ranging from CyberKnife applications and progress in respiratory tracking to the future of SRS and opportunities with Robotic IMRT. Guest presenters include:
Accuray will also showcase the latest capabilities of its newest offering, the CyberKnife VSI System, launched at last year's ASTRO meeting. Additionally, a new technology, Lung Optimized Treatment, which is pending 510(k) clearance by the U.S. Food and Drug Administration (FDA), will be demonstrated. The new technology is designed to expand the CyberKnife System's ability to non-invasively track tumor motion and potentially offer the option of fiducial-free treatments for more lung cancer patients.
"Throughout the past year CyberKnife radiosurgery has achieved significant growth globally as demonstrated by the treatment of the 100,000th patient, installation of the 206th CyberKnife System and growing use of the technology for extracranial indications including prostate and lung," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The research presented at ASTRO 2010 demonstrates the rapid adoption and expanding applications for CyberKnife radiosurgery as an evolving, patient-friendly cancer treatment."
ASTRO meeting attendees are invited to tour the nearby CyberKnife Centers of San Diego on Monday, November 1 and Tuesday, November 2. More information on these tours, the aforementioned in-booth presentations and CyberKnife posters and presentations of interest is available at www.accurayescalate.com.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more 100,000 patients worldwide and more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical evidence, growth in clinical applications and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; clinical applications, clinical studies, global growth, rate of adoption, and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission filed on August 31, 2010. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
|SOURCE Accuray Incorporated|
Copyright©2010 PR Newswire.
All rights reserved